Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

The recent ascent of targeted covalent inhibitors (TCI) in drug discovery brings new
opportunities and challenges to quantum chemical reactivity calculations supporting …

Covalent protein kinase inhibitors exploit currently noncatalytic cysteines in the adenosine
5′-triphosphate (ATP)-binding site via electrophiles directly appended to a reversible …

The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …

EGFR is a member of the ERBB family. It plays a significant role in cellular processes such
as growth, survival and differentiation via the activation of various signaling pathways. EGFR …

There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Cancer stands as a serious malady, posing substantial risks to human well‐being and
survival. This underscores the paramount necessity to explore and investigate novel …

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …

Inhibition of bacterial cell division is a novel mechanistic action in the development of new
antimicrobial agents. The FtsZ protein is an important antimicrobial drug target because of its …